|Bid||0.00 x 1000|
|Ask||0.00 x 4000|
|Day's Range||52.54 - 53.00|
|52 Week Range||49.96 - 70.05|
|PE Ratio (TTM)||86.51|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||1.60 (3.07%)|
|1y Target Est||58.30|
Bristol-Myers Squibbs (BMY) is anticipating key data readouts from multiple phase 3 trials evaluating Opdivo in indications such as gastric cancer, head and neck cancer, small cell lung cancer, and hepatocellular carcinoma, by the end of 2019. On April 18, Bristol-Myers Squibb announced that the FDA had granted priority review for a supplemental biologics application (or sBLA) seeking approval for Opdivo in the third-line small cell lung cancer (or SCLC) indication. The Prescription Drug User Fee Act (or PDUFA) date for this application has been set for August 16.
At end of Q1 2018, Bristol-Myers Squibb’s (BMY) Opdivo earned 40% of its revenues in the US market from the lung cancer indication, while the remaining US market revenues were attributable to demand for the drug in other tumor types. By the end of Q1 2018, the drug had managed to maintain its market share in the second-line lung cancer segment in the US.
In March, Merck & Company (MRK) and Eisai announced that Lenvima had received approval in Japan for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). Globally, Lenvima’s approval for the treatment of HCC in Japan became its first approval worldwide for the treatment of unresectable HCC.
In the first quarter, Bristol-Myers Squibb’s (BMY) Opdivo witnessed sales close to $1.5 billion, driven by a robust rise in demand across the approved indications of lung cancer, renal cell carcinoma (or RCC), head and neck cancer, and melanoma. Further, the company is also witnessing robust uptake of Opdivo as adjuvant therapy for melanoma patients. To know more about Opdivo as an adjuvant melanoma therapy, please read Opdivo Could Be Key Revenue Driver for Bristol-Myers Squibb in 2018.
Merck & Company (MRK) has entered into a global strategic oncology collaboration with Eisai for the worldwide codevelopment and co-commercialization of Eisai’s Lenvima. Merck and Eisai will jointly develop and commercialize Lenvima as a monotherapy and in combination with Keytruda.
Bristol-Myers Squibb Company (BMY) will hold an investor event on Monday, June 4, 2018 at 8:30 p.m. EDT (7:30 p.m. CDT) to discuss data presented at the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented from the company’s oncology portfolio, and address questions from investors and analysts. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
AstraZeneca formally opened its 163,000-square-foot lab and office complex Tuesday in HCP Inc.'s Britannia Cove in South San Francisco. It joins Merck and Bristol-Myers Squibb as traditional drug maker to expand operations in the Bay Area.
While Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) faded from last Wednesday highs, shares ultimately climbed about 3% that day. No, it wasn’t earnings or a new drug that gave TEVA stock a bump. Instead, it was Warren Buffett.
Major equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY), and GW Pharmaceuticals PLC (NASDAQ: GWPH). All you have to do is sign up today for this free limited time offer by clicking the link below.
Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.
In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.
Today, Immunomedics (IMMU) announced positive results from a Phase 2 trial evaluating its investigational antibody drug conjugate (or ADC) sacituzumab govitecan in patients suffering from estrogen receptor-positive (or ER+)/human epidermal growth factor receptor 2-negative (or HER2-) metastatic breast cancer who have previously received at least two therapies. The investigational ADC therapy demonstrated an overall response rate of 31% in these heavily pretreated patients. Immunomedics plans to file its first biologics license application with the FDA later this month for the approval of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer (mTNBC).
The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.
On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.
Bristol-Myers Squibb Company today announced that data from over 70 Company-sponsored studies and collaborations evaluating its oncology compounds across more than 20 types of cancer will be featured at the American Society of Clinical Oncology Annual Meeting 2018 in Chicago from June 1-5.
Gilead Sciences’ (GILD) Viread sales decreased 63% from $260 million in Q1 2017 to $97 million in Q1 2018. Epclusa sales, which accounted for 12% of Gilead’s total antiviral product sales in the first quarter, decreased from $892 million in Q1 2017 to $536 million in Q1 2018.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would not buy Chesapeake Energy Corporation (NYSE: CHK ) because there's too much natural gas. Cramer would take profits in Adaptimmune ...
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Clorox : "Clorox is caught up in this whole vortex of the 10-year Treasury going above 3 percent yield.
After topping the $110 level in March 2018, shares of Nektar Therapeutics (NASDAQ:NKTR) are in a downtrend. It is worth noting that even though Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Endo International PLC (NASDAQ:ENDP) are starting to attract investors, NKTR stock is more attractive because of the drug’s inherent properties. Nektar collaborated with Bristol-Myers Squibb Company (NYSE:BMY) to develop NKTR-214 in clinical trials.
Bristol-Myers Squibb (BMY) generated $1.1 billion from operating activities in 1Q18, which compares to $861 million in 1Q17. The increase was primarily attributable to the timing of cash collections and payments in business operations of ~$800 million, partially offset by lower litigation settlement proceeds of ~$500 million related to Merck’s Keytruda in 2017.
Bristol-Myers Squibb’s (BMY) total revenues have increased 5%, from $4.9 billion in 1Q17 to $5.2 billion in 1Q18. For fiscal 2018 and 2019, the company is expected to generate total revenues of $21.7 billion and $22.9 billion, respectively.
Bristol-Myers Squibb Company will take part in the UBS 2018 Global Healthcare Conference on Tuesday, May 22, 2018, in New York. Charles Bancroft, executive vice president, Chief Financial Officer and Head of Global Business Operations, will answer questions about the company at 11:30 a.m.
Bristol-Myers Squibb’s (BMY) prioritized brands include Opdivo, Eliquis, Orencia, Sprycel, Yervoy, and Empliciti. Total Opdivo sales increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18. The drug registered strong growth in the US market as well as non-US markets. Its US sales increased 23%, from $761 million in 1Q17 to $938 million in 1Q18. Opdivo’s non-US sales increased 57%, from $366 million in 1Q17 to $573 million in 1Q18.
Bristol-Myers Squibb’s (BMY) business strategy is to combine the scale and capabilities of a pharmaceutical company with the speed and agility of an innovation-driven biotechnology industry. The company’s strategic priorities include the following: driving business performance continuing to build a strong IO (immuno-oncology) franchise maintaining a diversified product portfolio maintaining a disciplined approach to capital allocation Key developments in 2018